A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Cautionary Note Regarding Forward-Looking Statements This Annual Report on Form 10-K (this Annual Report) contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend,” “aim,” "goal," "target," "continue," "hope," "may" and similar words. These forward-looking statements include, among other things, statements regarding our financial and operating performance; acquisitions; clinical trials; business plans and product performance; new and anticipated product approvals and launches; intellectual property; regulations and accounting pronouncements; legal proceedings; tax matters and regulations; and macroeconomic and geopolitical conditions.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 20.1B | 20.1B | 16.7B | 14.2B | 12.7B | 11.9B |
| Net Income | 2.9B | 2.9B | 1.9B | 1.6B | 642M | 985M |
| EPS | $1.94 | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 |
| Free Cash Flow | 3.7B | 3.7B | 2.6B | 1.8B | 938M | 1.3B |
| ROIC | 9.1% | 9.4% | 6.3% | 6.9% | 4.1% | 5.1% |
| Gross Margin | 69.0% | 69.0% | 68.6% | 69.5% | 68.8% | 68.8% |
| Debt/Equity | 0.48 | 0.48 | 0.58 | 0.50 | 0.51 | 0.55 |
| Dividends/Share | $0.00 | - | $0.00 | $0.02 | $0.04 | $0.04 |
| Operating Income | 3.6B | 3.6B | 2.6B | 2.3B | 1.6B | 1.2B |
| Operating Margin | 18.0% | 18.0% | 15.5% | 16.5% | 13.0% | 10.1% |
| ROE | 12.0% | 12.6% | 8.5% | 8.1% | 3.8% | 6.2% |
| Shares Outstanding | 1,494M | 1,494M | 1,482M | 1,467M | 1,427M | 1,428M |
BOSTON SCIENTIFIC CORP passes 4 of 9 quality checks, suggesting mixed fundamentals.
BOSTON SCIENTIFIC CORP trades at 32.6x trailing earnings, compared to its 15-year median P/E of 52.6x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 25.6x vs a median of 46.1x. The company's 5-year average ROIC is 6.4% with a gross margin of 68.9%. At current prices, the estimated annualized return to fair value is +28.1%.
BOSTON SCIENTIFIC CORP (BSX) has a current P/E ratio of 32.6, compared to its historical median P/E of 52.6. The stock is currently considered Fair based on its historical valuation range.
BOSTON SCIENTIFIC CORP (BSX) has a 5-year average return on invested capital (ROIC) of 6.4%. This is below average and may indicate limited pricing power.
BOSTON SCIENTIFIC CORP (BSX) has a market capitalization of $94.4B. It is classified as a large-cap stock.
BOSTON SCIENTIFIC CORP (BSX) does not currently pay a regular dividend.
Based on historical P/E analysis, BOSTON SCIENTIFIC CORP (BSX) appears fair. The current P/E of 32.6 is 38% below its historical median of 52.6. The estimated fair value CAGR (P/E method) is 1.5%.
BOSTON SCIENTIFIC CORP (BSX) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
BOSTON SCIENTIFIC CORP (BSX) reported annual revenue of $20.1 billion in its most recent fiscal year, based on SEC EDGAR filings.
BOSTON SCIENTIFIC CORP (BSX) has a net profit margin of 14.4%. This is a healthy margin.
BOSTON SCIENTIFIC CORP (BSX) generated $3.7 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
BOSTON SCIENTIFIC CORP (BSX) has a debt-to-equity ratio of 0.48. This indicates a conservatively financed balance sheet.
BOSTON SCIENTIFIC CORP (BSX) reported earnings per share (EPS) of $1.94 in its most recent fiscal year.
BOSTON SCIENTIFIC CORP (BSX) has a return on equity (ROE) of 12.6%. This indicates moderate shareholder returns.
BOSTON SCIENTIFIC CORP (BSX) has a 5-year average gross margin of 68.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 19 years of financial data for BOSTON SCIENTIFIC CORP (BSX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BOSTON SCIENTIFIC CORP (BSX) has a book value per share of $16.22, based on its most recent annual SEC filing.